Straits Times Index
3,297.55 -26.98 (-0.81%) S&P 500
5,431.60 -2.14 (-0.04%) Dow
38,589.16 -57.94 (-0.15%) Nasdaq
17,688.88 +21.28 (+0.12%) Bitcoin USD
66,338.37 +187.94 (+0.28%) CMC Crypto 200
1,382.78 -35.09 (-2.47%)
STOK Aug 2024 10.000 call
- Business Wire
Stoke Therapeutics to Present at Upcoming Investor Conferences in June
BEDFORD, Mass., June 03, 2024--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced that management will present at the following upcoming investor conferences:
- GuruFocus.com
Insider Sale: CEO Edward M. Kaye of Stoke Therapeutics Inc (STOK) Sells 42,350 Shares
On May 20, 2024, Edward M. Kaye, MD, Chief Executive Officer of Stoke Therapeutics Inc (NASDAQ:STOK), executed a significant stock transaction, selling 42,350 shares of the company.
- Business Wire
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
BEDFORD, Mass., May 17, 2024--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced that, effective on May 15, 2024, the company granted stock options of common stock to Thomas Leggett, the Company’s newly-appointed Chief Financial Officer, and four other new employees as a material inducement to their employment in accordance with Nasdaq Listing
